BDSX
Biodesix Inc
$21.42
-0.73 (-3.30%)
At close · Jul 10
Market Cap
$216.53M
Shares
10,108,580
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$88.5M
+24.1%
FY2025
Net Income
-$35.27M
+17.9%
FY2025
Operating Margin
-31.5%
+16.9pp
FY2025
Diluted EPS
-$4.67
+29.2%
FY2025
Operating Cash Flow
-$23.27M
+52.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|---|
| $108M – $114M | $96.1M | $88.5M | $71.32M | $49.09M | $38.21M | $54.51M | $45.56M | |
| — | $12.42M | $12M | $9.56M | $9.99M | $13.1M | $12.79M | $10.82M | |
| — | $7.9M | $7.56M | $7.57M | — | — | — | — | |
| — | $91.36M | $87.55M | $80.45M | $67.39M | $61.46M | $50.52M | $34.86M | |
| — | $2.03M | $2.03M | $2.01M | $1.98M | $1.98M | $1.95M | $2.06M | |
| — | $5.63M | $5.67M | $5.77M | $3.33M | $3.6M | $3.18M | $2.9M | |
| — | $121.03M | $116.37M | $105.82M | $90.43M | $88.8M | $95.45M | $68.49M | |
| — | -$24.94M | -$27.87M | -$34.5M | -$41.34M | -$50.59M | -$40.94M | -$22.93M | |
| — | — | -31.5% | -48.37% | -84.22% | -132.39% | -75.11% | -50.34% | |
| — | -$19.31M | -$22.2M | -$28.73M | -$38.01M | -$46.99M | -$37.76M | -$20.03M | |
| — | $8.01M | $7.72M | $8.26M | $9.54M | $8.07M | $4.51M | $7.6M | |
| — | -$7.02M | -$7.39M | -$8.43M | -$10.8M | -$14.86M | -$2.22M | -$8.42M | |
| — | — | $0 | $0 | $0 | $0 | $0 | $0 | |
| — | -$31.96M | -$35.27M | -$42.93M | -$52.15M | -$65.45M | -$43.16M | -$31.35M | |
| — | — | -39.85% | -60.19% | -106.23% | -171.27% | -79.18% | -68.81% | |
| USD/shares | — | — | -$4.67 | -$6.60 | -$12.80 | -$31.00 | — | — |
| USD/shares | — | — | -$4.67 | -$6.60 | -$12.80 | -$31.00 | — | — |
| shares | — | — | 7.55M | 6.48M | 4.11M | 2.11M | 1.37M | 241.9K |
| shares | — | — | 7.55M | 6.48M | 4.11M | 2.11M | 1.37M | 241.9K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Diagnostics & Research median 2.92×
EV/EBIT
—
Diagnostics & Research median 31.02×
P/E (TTM)
—
Diagnostics & Research median 32.16×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|
| Diagnostic Tests | $79,197,000 | $64,708,000 | — | $34,538,000 | $48,937,000 | $40,919,000 | $17,315,000 |
| Development Services | $9,302,000 | $6,615,000 | $3,895,000 | — | — | — | — |
| Biopharma Services and Other | — | — | — | $3,674,000 | — | — | — |
| Lung Diagnostic Testing | — | — | $45,192,000 | — | — | — | — |
| Service | — | — | — | — | $5,569,000 | $4,638,000 | $7,237,000 |